H. Shigematsu

Oncology · 2005–2006

A researcher in the Science corpus: 3 papers; trusts 1 researcher and is trusted by 1 researcher here, as inferred from the citation graph.

Subfields

Whom H. Shigematsu trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

  1. C. Sawyers
  2. William Pao
  3. Mathew Garnett
  4. Vincent A. Miller
  5. M. Kris

Who trusts H. Shigematsu overall

  1. Adi F. Gazdar
  2. M. Moasser
  3. N. Hynes
  4. M. Wieduwilt
  5. Xuewu Zhang
  6. C. Yun

Papers from H. Shigematsu's perspective

Ordered by how strongly the researchers H. Shigematsu trusts endorse each paper. Same corpus, a different order for every researcher.

  1. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. (New England Journal of Medicine)
  2. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. (New England Journal of Medicine)
  3. Gefitinib-Sensitizing EGFR Mutations in Lung Cancer Activate Anti-Apoptotic Pathways (Science)
  4. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. (Journal of Clinical Oncology)
  5. Targeted cancer therapy (Nature)
  6. The deaf and the dumb: the biology of ErbB-2 and ErbB-3. (Experimental Cell Research)
  7. Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor (Science)
  8. Anticancer drugs: To the rescue? (Nature reviews. Drug discovery)
  9. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. (New England Journal of Medicine)
  10. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. (Journal of the National Cancer Institute)

Their papers